Market Lifecycle Stage
The global heart failure market is currently in the expansion phase, with increasing adoption of new therapies and technological advancements. The rising number of heart failure patients globally, alongside advancements in drug development and medical devices, is fuelling market growth. The introduction of personalized treatments and devices that enhance heart function is expected to continue propelling the market forward.
Impact
Technological advancements in drug development, cardiac devices, and patient monitoring systems are significantly impacting the global heart failure market. The development of novel heart failure treatments and wearable devices is improving patient outcomes and enabling better management of heart failure symptoms, especially in chronic and severe cases.
Market Segmentation
Segmentation 1: By Drug Class
ACE Inhibitors
Beta Blockers
Diuretics
Angiotensin 2 Receptor Antagonists
Aldosterone Antagonists
Others
The market is largely driven by ACE inhibitors and beta blockers, which are commonly used to manage blood pressure and heart function. Diuretics are a significant segment, often used to reduce fluid retention in heart failure patients. Newer drug classes such as Angiotensin 2 receptor antagonists are gaining traction as alternatives for patients who cannot tolerate ACE inhibitors.
Segmentation 2: by Region
North America
Europe
Asia-Pacific
Rest-of-the-WorldThe market is dominated by North America, with the U.S. leading the market, driven by advanced healthcare systems and a high prevalence of cardiovascular diseases. Europe and Asia-Pacific are also significant markets, with Europe benefiting from strong healthcare infrastructure and Asia-Pacific seeing rapid growth due to increasing healthcare access and rising heart failure incidences.
Demand – Drivers and Limitations
Demand Drivers for the Global Heart Failure Market:
Increasing prevalence of heart failure, especially among the aging population
Advancements in drug development and medical devices for heart failure
Growing demand for personalized treatments
Rising awareness and availability of healthcare services
Limitations for the Global Heart Failure Market:
High costs associated with advanced heart failure treatments and devices
Complexity in the diagnosis and treatment of heart failure
How can this report add value to an organization?
Product/Innovation:The report provides an in-depth analysis of various drug classes and therapeutic products, helping organizations understand the evolving landscape of heart failure treatments. It outlines how companies can leverage new treatment modalities and technologies to innovate and improve patient outcomes.
Growth/Marketing:With the increasing demand for heart failure treatments, companies are focusing on expanding their market presence. The report offers strategies for business growth, including opportunities in underserved markets and leveraging new therapies to enhance marketing efforts.
Competitive:A detailed competitive landscape analysis helps organizations benchmark their market standing against key players such as Novartis, and Pfizer. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global heart failure market.
Key Market Players and Competition Synopsis
The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global heart failure market. Leading players in the global heart failure market include:
Novartis AG
Pfizer Inc.
Bayer AG
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Executive Summary
- Scope of Study
- Definition
- Inclusion and Exclusion Criteria
- 1. Global Heart Failure: Industry Outlook
- 1.1 Market Overview and Ecosystem
- 1.2 Market Trends
- 1.3 Epidemiological Analysis of Heart Failure
- 1.3.1 U.S.
- 1.3.2 EU5
- 1.3.3 Rest-of-the-World
- 1.4 Clinical Trials
- 1.5 Regulatory Landscape Analysis
- 1.5.1 Legal Requirement and Framework in U.S.
- 1.5.2 Legal Requirement and Framework in E.U.
- 1.5.3 Legal Requirement and Framework in Asia-Pacific
- 1.5.4 Legal Requirement and Framework in Rest-of-the-World
- 1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Restraints
- 1.6.4 Market Opportunities
- 2. Global Heart Failure Market, by Drug Class, $Million, 2023-2035
- 2.1 Introduction
- 2.2 ACE Inhibitors
- 2.3 Beta Blockers
- 2.4 Diuretics
- 2.5 Angiotensin 2 Receptor Antagonist
- 2.6 Aldosterone Antagonist
- 2.7 Others
- 3. Global Heart Failure Market, by Region, $Million, 2023-2035
- 3.1 North America
- 3.1.1 Key Findings
- 3.1.2 Market Dynamics
- 3.1.3 Market Sizing and Forecast
- 3.1.3.1 North America Heart Failure Market (by Country)
- 3.1.3.1.1 U.S.
- 3.1.3.1.2 Canada
- 3.2 Europe
- 3.2.1 Key Findings
- 3.2.2 Market Dynamics
- 3.2.3 Market Sizing and Forecast
- 3.2.3.1 Europe Heart Failure Market (by Country)
- 3.2.3.1.1 Germany
- 3.2.3.1.2 France
- 3.2.3.1.3 U.K.
- 3.2.3.1.4 Italy
- 3.2.3.1.5 Spain
- 3.2.3.1.6 Rest-of-Europe
- 3.3 Asia-Pacific
- 3.3.1 Key Findings
- 3.3.2 Market Dynamics
- 3.3.3 Market Sizing and Forecast
- 3.3.3.1 Asia-Pacific Heart Failure Market (by Country)
- 3.3.3.1.1 Japan
- 3.3.3.1.2 China
- 3.3.3.1.3 India
- 3.3.3.1.4 Rest-of-Asia-Pacific
- 3.4 Rest-of-the World
- 3.4.1 Key Findings
- 3.4.2 Market Dynamics
- 3.4.3 Market Sizing and Forecast
- 4. Global Heart Failure Market-Competitive Benchmarking and Company Profiles
- 4.1 Competitive Landscape
- 4.1.1 Key Strategies and Developments by Company
- 4.1.1.1 Funding Activities
- 4.1.1.2 Mergers and Acquisitions
- 4.1.1.3 Regulatory Approvals
- 4.1.1.4 Partnerships, Collaborations and Business Expansions
- 4.1.2 Key Developments Analysis
- 4.2 Company Profiles
- 4.2.1 Amgen Inc.
- 4.2.1.1 Overview
- 4.2.1.2 Product Portfolio
- 4.2.1.3 Target Customers
- 4.2.1.4 Key Personnels
- 4.2.1.5 Analyst View
- 4.2.2 Pfizer Inc.
- 4.2.2.1 Overview
- 4.2.2.2 Product Portfolio
- 4.2.2.3 Target Customers
- 4.2.2.4 Key Personnels
- 4.2.2.5 Analyst View
- 4.2.3 Novartis AG
- 4.2.3.1 Overview
- 4.2.3.2 Product Portfolio
- 4.2.3.3 Target Customers
- 4.2.3.4 Key Personnels
- 4.2.3.5 Analyst View
- 4.2.4 AstraZeneca Plc
- 4.2.4.1 Overview
- 4.2.4.2 Product Portfolio
- 4.2.4.3 Target Customers
- 4.2.4.4 Key Personnels
- 4.2.4.5 Analyst View
- 4.2.5 Merck & Co., Inc.
- 4.2.5.1 Overview
- 4.2.5.2 Product Portfolio
- 4.2.5.3 Target Customers
- 4.2.5.4 Key Personnels
- 4.2.5.5 Analyst View
- 4.2.6 Bristol-Myers Squibb (BMS)
- 4.2.6.1 Overview
- 4.2.6.2 Product Portfolio
- 4.2.6.3 Target Customers
- 4.2.6.4 Key Personnels
- 4.2.6.5 Analyst View
- 4.2.7 GlaxoSmithKline (GSK)
- 4.2.7.1 Overview
- 4.2.7.2 Product Portfolio
- 4.2.7.3 Target Customers
- 4.2.7.4 Key Personnels
- 4.2.7.5 Analyst View
- 4.2.8 Novo Nordisk
- 4.2.8.1 Overview
- 4.2.8.2 Product Portfolio
- 4.2.8.3 Target Customers
- 4.2.8.4 Key Personnels
- 4.2.8.5 Analyst View
- 4.2.9 Bayer AG
- 4.2.9.1 Overview
- 4.2.9.2 Product Portfolio
- 4.2.9.3 Target Customers
- 4.2.9.4 Key Personnels
- 4.2.9.5 Analyst View
- 5. Research Methodology
- List of Figures
- Figure 1: Global Heart Failure Market Dynamics Impact Analysis
- Figure 2: Global Heart Failure Market Coverage
- Figure 3: Global Heart Failure Market Key Trends, Impact Analysis
- Figure 4: Global Heart Failure Market, Competitive Landscape
- List of Tables
- Table 1: Global Heart Failure Market, Comparative Analysis
- Table 2: Global Heart Failure Market, Regulatory Scenario
- Table 3: Global Heart Failure Market Dynamics, Impact Analysis
- Table 4: Global Heart Failure Market (by Drug Class)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook